• Diabetes Core Update - Special Edition - Lipids Beyound Statins and LDL

  • 2024/09/18
  • 再生時間: 27 分
  • ポッドキャスト

Diabetes Core Update - Special Edition - Lipids Beyound Statins and LDL

  • サマリー

  • In this special episode titled “Lipids – Beyond Statins and LDL Cholesterol”, our host, Dr. Neil Skolnik will discuss with two expert guests the details of treatment for LDL-Cholesterol, Triglycerides, and other lipid risk markers. This special episode is supported by an independent educational grant from Amarin.

    Presented by:

    Neil Skolnik, M.D., Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health

    James Underberg, M.D. , Clinical Assistant Professor of Medicine at NYU School of Medicine and the NYU Center for Prevention of Cardiovascular Disease, Director of the Bellevue Hospital Lipid Clinic, and Past President of the National Lipid Association.

    Layla A. Abushamat, M.D., MPH, Assistant Professor, Department of Medicine in the Division of Atherosclerosis and Vascular Medicine, Baylor College of Medicine, Houston, Texas

    Selected references referred to the in the Podcast:

    1. Icosapent Ethyl: REDUCE-IT - N Engl J Med 2019; 380:11-22

    2. Omega-3 Fatty Acids: STRENGTH trial - JAMA. 2020;324(22):2268-2280

    3. Lipoprotein(a) Blood Levels and Cardiovascular Risk Reduction With Icosapent Ethyl. JACC. 2024 Apr, 83 (16) 1529–1539

    4. Icosapent ethyl following acute coronary syndrome. European Heart Journal 2024; 45:1173–1176

    5. Cardiovascular Disease and Risk Management: ADA Standards of Care in Diabetes—2024. Diabetes Care 2024;47(supp 1): S179–S218

    続きを読む 一部表示
activate_samplebutton_t1

あらすじ・解説

In this special episode titled “Lipids – Beyond Statins and LDL Cholesterol”, our host, Dr. Neil Skolnik will discuss with two expert guests the details of treatment for LDL-Cholesterol, Triglycerides, and other lipid risk markers. This special episode is supported by an independent educational grant from Amarin.

Presented by:

Neil Skolnik, M.D., Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health

James Underberg, M.D. , Clinical Assistant Professor of Medicine at NYU School of Medicine and the NYU Center for Prevention of Cardiovascular Disease, Director of the Bellevue Hospital Lipid Clinic, and Past President of the National Lipid Association.

Layla A. Abushamat, M.D., MPH, Assistant Professor, Department of Medicine in the Division of Atherosclerosis and Vascular Medicine, Baylor College of Medicine, Houston, Texas

Selected references referred to the in the Podcast:

1. Icosapent Ethyl: REDUCE-IT - N Engl J Med 2019; 380:11-22

2. Omega-3 Fatty Acids: STRENGTH trial - JAMA. 2020;324(22):2268-2280

3. Lipoprotein(a) Blood Levels and Cardiovascular Risk Reduction With Icosapent Ethyl. JACC. 2024 Apr, 83 (16) 1529–1539

4. Icosapent ethyl following acute coronary syndrome. European Heart Journal 2024; 45:1173–1176

5. Cardiovascular Disease and Risk Management: ADA Standards of Care in Diabetes—2024. Diabetes Care 2024;47(supp 1): S179–S218

Diabetes Core Update - Special Edition - Lipids Beyound Statins and LDLに寄せられたリスナーの声

カスタマーレビュー:以下のタブを選択することで、他のサイトのレビューをご覧になれます。